Status: current, Sufficiently defined by necessary conditions definition status. Date: 31-Jul 2021. Module: SNOMED CT core module
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module | 
| 4555462016 | Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive | SNOMED CT core module | 
| 4555463014 | Abacavir (as abacavir sulfate) 300 mg and lamivudine 150 mg and zidovudine 300 mg oral tablet | en | Synonym | Active | Entire term case insensitive | SNOMED CT core module | 
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values | 
| Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | Plays role | Antiretroviral therapeutic role | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | Has precise active ingredient | Zidovudine | true | Inferred relationship | Existential restriction modifier | 3 | |
| Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | Has basis of strength substance | Abacavir | true | Inferred relationship | Existential restriction modifier | 2 | |
| Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | Has unit of presentation | Tablet | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | Has precise active ingredient | Abacavir sulfate | true | Inferred relationship | Existential restriction modifier | 2 | |
| Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator unit | Tablet | true | Inferred relationship | Existential restriction modifier | 3 | |
| Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | Has basis of strength substance | Lamivudine | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator unit | Tablet | true | Inferred relationship | Existential restriction modifier | 2 | |
| Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator unit | milligram | true | Inferred relationship | Existential restriction modifier | 2 | |
| Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | Is a | Product containing only abacavir and lamivudine and zidovudine in oral dose form (medicinal product form) | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | Has precise active ingredient | Lamivudine | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator unit | Tablet | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | Has basis of strength substance | Zidovudine | true | Inferred relationship | Existential restriction modifier | 3 | |
| Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator unit | milligram | true | Inferred relationship | Existential restriction modifier | 3 | |
| Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | Conventional release oral tablet | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely abacavir (as abacavir sulfate) 300 milligram and lamivudine 150 milligram and zidovudine 300 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator unit | milligram | true | Inferred relationship | Existential restriction modifier | 1 | 
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group | 
This concept is not in any reference sets